Registered title, quoted from ClinicalTrials.gov
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07539753, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
age <60 years and postmenopausal status defined as at least 12 consecutive months of spontaneous amenorrhea without other pathological or physiological causes, with estradiol (E2) and follicle-stimulating hormone (FSH) levels within the postmenopausal range; or
Inclusion criterion 3
2.Histologically or cytologically confirmed HR-positive, HER2-negative breast cancer in female patients, with evidence of locally recurrent or metastatic disease that is not amenable to curative surgery or radiotherapy, and with no clinical indication for chemotherapy.
Inclusion criterion 5
3.Presence of brain metastases confirmed by MRI, with at least one measurable intracranial lesion ≥1 cm according to RECIST version 1.1. Measurable extracranial disease is not required.
Inclusion criterion 8
7.Prior stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) is permitted, provided that the currently active measurable disease has not been previously treated with radiotherapy.
Inclusion criterion 18
8.Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and must agree to use a medically acceptable highly effective method of contraception during the study and for 1 year after the last dose of study treatment.
Inclusion criterion 19
6.Prior whole-brain radiotherapy (WBRT) .
Exclusion criterion 8
10.History of immunodeficiency, including HIV infection, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, other acquired or congenital immunodeficiency disorders, or prior organ transplantation.
Exclusion criterion 16
4.ECOG performance status 0-2, and an estimated life expectancy of at least 12 weeks at the time of enrollment.
Inclusion criterion 9
absolute neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10\^9/L), without growth factor support within 14 days;
Inclusion criterion 12
platelet count (PLT) ≥ 100,000/mm³ (100 × 10\^9/L), without corrective treatment within 7 days;
Inclusion criterion 13
hemoglobin (Hb) ≥ 9 g/dL (90 g/L), without corrective treatment within 7 days;
Inclusion criterion 14
serum creatinine (Scr) ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance ≥ 60 mL/min;
Inclusion criterion 15
total bilirubin ≤ 1.5 × ULN;
Inclusion criterion 16
aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 × ULN, or ≤ 5 × ULN for patients with liver metastases.
Inclusion criterion 17
5.If the patient is receiving corticosteroids, the corticosteroid dose must be stable or decreasing for at least 5 days before the brain gadolinium-enhanced MRI (Gd-MRI). This MRI must be performed within 28 days before enrollment. Patients who require an increased steroid dose before treatment, or who are receiving an unstable steroid dose, are not eligible.
Inclusion criterion 10
1.Prior pathological diagnosis of HER2-positive breast cancer.
Exclusion criterion 1
11.History of malignancy other than breast cancer.
Exclusion criterion 17
8.Pregnant or breastfeeding women.
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07539753, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1.Female patients aged 18 to 75 years, who are postmenopausal or premenopausal/perimenopausal, and meet at least one of the following conditions:
- prior bilateral oophorectomy; or age ≥60 years; or
- age <60 years and postmenopausal status defined as at least 12 consecutive months of spontaneous amenorrhea without other pathological or physiological causes, with estradiol (E2) and follicle-stimulating hormone (FSH) levels within the postmenopausal range; or
- premenopausal or perimenopausal women are also eligible if they are willing to receive treatment with an LHRH agonist during the study.
- 2.Histologically or cytologically confirmed HR-positive, HER2-negative breast cancer in female patients, with evidence of locally recurrent or metastatic disease that is not amenable to curative surgery or radiotherapy, and with no clinical indication for chemotherapy.
- HR-positive is defined as ER-positive and/or PR-positive, with ≥1% of tumor cells showing positive staining, as confirmed by the investigator at the study site.
- HER2-negative is defined as IHC 0 or 1+, or ISH-negative, defined as a HER2/CEP17 ratio <2.0 or an average HER2 copy number <4.0, as confirmed by the investigator at the study site.
- 3.Presence of brain metastases confirmed by MRI, with at least one measurable intracranial lesion ≥1 cm according to RECIST version 1.1. Measurable extracranial disease is not required.
- 4.ECOG performance status 0-2, and an estimated life expectancy of at least 12 weeks at the time of enrollment.
- 5.If the patient is receiving corticosteroids, the corticosteroid dose must be stable or decreasing for at least 5 days before the brain gadolinium-enhanced MRI (Gd-MRI). This MRI must be performed within 28 days before enrollment. Patients who require an increased steroid dose before treatment, or who are receiving an unstable steroid dose, are not eligible.
- 6.Screening laboratory values must meet the following criteria( and should be obtained within 14 days prior to registration)::
- absolute neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10\^9/L), without growth factor support within 14 days;
- platelet count (PLT) ≥ 100,000/mm³ (100 × 10\^9/L), without corrective treatment within 7 days;
- hemoglobin (Hb) ≥ 9 g/dL (90 g/L), without corrective treatment within 7 days;
- serum creatinine (Scr) ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance ≥ 60 mL/min;
- total bilirubin ≤ 1.5 × ULN;
- aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 × ULN, or ≤ 5 × ULN for patients with liver metastases.
- 7.Prior stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) is permitted, provided that the currently active measurable disease has not been previously treated with radiotherapy.
- 8.Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and must agree to use a medically acceptable highly effective method of contraception during the study and for 1 year after the last dose of study treatment.
- 9.Ability and willingness to signed the informed consent form prior to patient entry.
Exclusion Criteria:
- 1.Prior pathological diagnosis of HER2-positive breast cancer.
- 2.Prior disease progression on dalpiciclib in the metastatic setting.
- 3.Primary endocrine resistance, defined as either:
- disease recurrence or progression within 2 years of starting adjuvant endocrine therapy; or
- disease progression within 6 months of first-line endocrine therapy for advanced or metastatic disease.
- 4.Patients considered not suitable for endocrine therapy in the judgment of the investigator, including patients with symptomatic visceral disease, disseminated visceral involvement, or a risk of life-threatening complications in the short term, such as uncontrolled massive effusions (pleural, pericardial, or peritoneal), lymphangitic carcinomatosis of the lung, or >50% liver involvement.
- 5.Presence of leptomeningeal metastases.
- 6.Prior whole-brain radiotherapy (WBRT) .
- 7.Any severe neurologic symptoms caused by central nervous system metastases.
- 8.Pregnant or breastfeeding women.
- 9.Any serious uncontrolled clinical disease or infection that, in the investigator's judgment, cannot be adequately controlled with appropriate treatment or may impair the patient's ability to tolerate study treatment, including but not limited to:
- serious cardiovascular events such as syncope of cardiovascular origin, pathologic ventricular arrhythmias (including but not limited to ventricular tachycardia or ventricular fibrillation), or cardiac arrest;
- end-stage renal disease;
- severe liver disease;
- active systemic bacterial infection.
- 10.History of immunodeficiency, including HIV infection, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, other acquired or congenital immunodeficiency disorders, or prior organ transplantation.
- 11.History of malignancy other than breast cancer.
- 12.Inability to swallow oral medication, or presence of chronic diarrhea, intestinal obstruction, or other conditions that may interfere with the administration or absorption of study drugs.
- 13.History of allergy or hypersensitivity to any study drug or any of its components.
Quoted from ClinicalTrials.gov, NCT07539753, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07539753, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.